Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prozac For Premenstrual Dysphoric Disorder May Get "Fem"-inine Touch

Executive Summary

Lilly is planning to market its blockbuster antidepressant Prozac (fluoxetine) with separate packaging and a new name for treatment of premenstrual dysphoric disorder.

You may also be interested in...



Lilly Sarafem PMDD Therapy Approved With Patient Package Insert

Lilly's pre-menstrual dysphoric disorder packaging for fluoxetine (Sarafem) will include a patient package insert.

Lilly Sarafem PMDD Therapy Approved With Patient Package Insert

Lilly's pre-menstrual dysphoric disorder packaging for fluoxetine (Sarafem) will include a patient package insert.

Lilly Fluoxetine For Premenstrual Dysphoria Merits Separate Indication

Labeling for Lilly's fluoxetine (Prozac) should include a separate indication for premenstrual dysphoric disorder, FDA's Psychopharmacologic Drugs Advisory Committee agreed Nov. 3.

Related Content

UsernamePublicRestriction

Register

PS035147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel